Investor Alert

press release

Sept. 1, 2021, 8:00 a.m. EDT

Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference

SALT LAKE CITY, Sept. 1, 2021 /PRNewswire/ -- Lipocine Inc. /zigman2/quotes/202742746/composite LPCN +0.36% , a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Presentation time: September 13, 2021 starting at 7:00 a.m. EST
Webcast link: https://journey.ct.events/view/6ad0ee65-750c-40c8-974f-d653d6d67c25

A webcast of Lipocine's presentation will be available on-demand as of 7:00 am ET, Monday, September 13, 2021, thorough the H.C. Wainwright conference portal, on Lipocine's website under "Events & Presentations" in the Investors section or using the webcast link above.  The webcast will be available on the Lipocine's website for 90 days. 

About Lipocine Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1107 and LPCN 1154. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH.   TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.  For more information, please visit www.lipocine.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/lipocine-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301366743.html

SOURCE Lipocine Inc.


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

US : U.S.: Nasdaq
$ 0.71
+0.0025 +0.36%
Volume: 320,119
Aug. 12, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$62.44 million
Rev. per Employee


Partner Center

Link to MarketWatch's Slice.